Drapkin Kimberlee C — SEC Form 4 filings
SEC reporting owner CIK 1340881. 12 Form 4 filings on record with FilingPulse; latest filed 2026-06-15.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-03-25 to 2026-06-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| KINETA, INC./DE (KANT) | Director | 3 | — | — | 7 |
| Acumen Pharmaceuticals, Inc. (ABOS) | Director | 3 | — | — | 5 |
| Climb Bio, Inc. (CLYM) | Director | 3 | — | — | 3 |
| LENZ Therapeutics, Inc. (LENZ) | Director | 3 | — | — | 3 |
Form 4 filings — Drapkin Kimberlee C
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-15 | 4 | LENZ Therapeutics, Inc. (LENZ) | Grant/award (A): 22,100 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Climb Bio, Inc. (CLYM) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) | Grant/award (A): 35,500 @ $0 · Grant/award (A): 53,250 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | KINETA, INC./DE (KANT) | Disposition to issuer (D): 13,794 · Disposition to issuer (D): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-25 | 4 | KINETA, INC./DE (KANT) | Option exercise (M): 12,500 @ $0.61 · Tax withholding (F): 4,706 @ $0.26 · Grant/award (A): 6,000 @ $0 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | LENZ Therapeutics, Inc. (LENZ) | Grant/award (A): 13,500 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Climb Bio, Inc. (CLYM) | Grant/award (A): 40,000 (derivative) @ $0 | EDGAR |
| 2025-06-05 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) | Grant/award (A): 12,800 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | Climb Bio, Inc. (CLYM) | Grant/award (A): 80,000 (derivative) @ $0 | EDGAR |
| 2024-09-05 | 4 | KINETA, INC./DE (KA) | Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Acumen Pharmaceuticals, Inc. (ABOS) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-03-25 | 4 | LENZ Therapeutics, Inc. (LENZ) | Grant/award (A): 27,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1340881 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →